CTMX Q4 2016 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q4 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+215.5% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$14M-226.9% margin

Net Income

-$14M-223.7% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+81.6%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$1M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$199M

Total Liabilities

$121M

Stockholders' Equity

$78M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$2M	+215.5%
Gross Profit	$6M	$2M	+215.5%
Operating Income	-$14M	-$12M	-23.5%
Net Income	-$14M	-$11M	-22.2%